| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA 90404, USA
1Correspondence: John Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA. E-mail: Cabot{at}jwci.org
Ceramide glycosylation, through glucosylceramide synthase (GCS), allows cellular escape from ceramide-induced programmed cell death. This glycosylation event confers cancer cell resistance to cytotoxic anticancer agents [Liu, Y. Y., Han, T. Y., Giuliano, A. E., and M. C. Cabot. (1999) J. Biol. Chem. 274, 1140–1146]. We previously found that glucosylceramide, the glycosylated form of ceramide, accumulates in adriamycin-resistant breast carcinoma cells, in vinblastine-resistant epithelioid carcinoma cells, and in tumor specimens from patients showing poor response to chemotherapy. Here we show that multidrug resistance can be increased over baseline and then totally reversed in human breast cancer cells by GCS gene targeting. In adriamycin-resistant MCF-7-AdrR cells, transfection of GCS upgraded multidrug resistance, whereas transfection of GCS antisense markedly restored cellular sensitivity to anthracyclines, Vinca alkaloids, taxanes, and other anticancer drugs. Sensitivity to the various drugs by GCS antisense transfection increased 7- to 240-fold and was consistent with the resumption of ceramide-caspase-apoptotic signaling. GCS targeting had little influence on cellular sensitivity to either 5-FU or cisplatin, nor did it modify P-glycoprotein expression or rhodamine-123 efflux. GCS antisense transfection did enhance rhodamine-123 uptake compared with parent MCF-7-AdrR cells. This study reveals that GCS is a novel mechanism of multidrug resistance and positions GCS antisense as an innovative force to overcome multidrug resistance in cancer chemotherapy.—Liu, Y.-Y., Han, T.-Y., Giuliano, A. E., and Cabot, M. C. Ceramide glycosylation potentiates cellular multidrug resistance.
Key Words: glucosylceramide synthase • antisense • breast cancer • apoptosis • chemotherapy
This article has been cited by other articles:
|
|
 |
|
  H. Wang, B. J. Maurer, Y.-Y. Liu, E. Wang, J. C. Allegood, S. Kelly, H. Symolon, Y. Liu, A. H. Merrill, Jr., V. Gouaze-Andersson, et al. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing Mol. Cancer Ther., September 1, 2008; 7(9): 2967 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Liu, J. Y. Yu, D. Yin, G. A. Patwardhan, V. Gupta, Y. Hirabayashi, W. M. Holleran, A. E. Giuliano, S. M. Jazwinski, V. Gouaze-Andersson, et al. A role for ceramide in driving cancer cell resistance to doxorubicin FASEB J, July 1, 2008; 22(7): 2541 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. van Vlerken, Z. Duan, M. V. Seiden, and M. M. Amiji Modulation of Intracellular Ceramide Using Polymeric Nanoparticles to Overcome Multidrug Resistance in Cancer Cancer Res., May 15, 2007; 67(10): 4843 - 4850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. George, T. Chen, and C. C. Taylor Src Tyrosine Kinase and Multidrug Resistance Protein-1 Inhibitions Act Independently but Cooperatively to Restore Paclitaxel Sensitivity to Paclitaxel-Resistant Ovarian Cancer Cells Cancer Res., November 15, 2005; 65(22): 10381 - 10388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gouaze, Y.-Y. Liu, C. S. Prickett, J. Y. Yu, A. E. Giuliano, and M. C. Cabot Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs Cancer Res., May 1, 2005; 65(9): 3861 - 3867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Norris-Cervetto, R. Callaghan, F. M. Platt, R. A. Dwek, and T. D. Butters Inhibition of Glucosylceramide Synthase Does Not Reverse Drug Resistance in Cancer Cells J. Biol. Chem., September 24, 2004; 279(39): 40412 - 40418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Liu, T. Y. Han, J. Y. Yu, A. Bitterman, A. Le, A. E. Giuliano, and M. C. Cabot Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells J. Lipid Res., May 1, 2004; 45(5): 933 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gouaze, J. Y. Yu, R. J. Bleicher, T.-Y. Han, Y.-Y. Liu, H. Wang, M. M. Gottesman, A. Bitterman, A. E. Giuliano, and M. C. Cabot Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy Mol. Cancer Ther., May 1, 2004; 3(5): 633 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Maggio, R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells Cancer Res., April 1, 2004; 64(7): 2590 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Watanabe, T. Kitano, T. Kondo, T. Yabu, Y. Taguchi, M. Tashima, H. Umehara, N. Domae, T. Uchiyama, and T. Okazaki Increase of Nuclear Ceramide through Caspase-3-Dependent Regulation of the "Sphingomyelin Cycle" in Fas-Induced Apoptosis Cancer Res., February 1, 2004; 64(3): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Silins, M. Nordstrand, J. Hogberg, and U. Stenius Sphingolipids suppress preneoplastic rat hepatocytes in vitro and in vivo Carcinogenesis, June 1, 2003; 24(6): 1077 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prinetti, L. Basso, V. Appierto, M. G. Villani, M. Valsecchi, N. Loberto, S. Prioni, V. Chigorno, E. Cavadini, F. Formelli, et al. Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells J. Biol. Chem., February 14, 2003; 278(8): 5574 - 5583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Shabbits and L. D. Mayer P-Glycoprotein Modulates Ceramide-mediated Sensitivity of Human Breast Cancer Cells to Tubulin-binding Anticancer Drugs Mol. Cancer Ther., January 1, 2002; 1(3): 205 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Senchenkov, T.-Y. Han, H. Wang, A. E. Frankel, T. J. Kottke, S. H. Kaufmann, and M. C. Cabot Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT388-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF Blood, September 15, 2001; 98(6): 1927 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leipelt, D. Warnecke, U. Zahringer, C. Ott, F. Muller, B. Hube, and E. Heinz Glucosylceramide Synthases, a Gene Family Responsible for the Biosynthesis of Glucosphingolipids in Animals, Plants, and Fungi J. Biol. Chem., August 31, 2001; 276(36): 33621 - 33629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Chalfant, B. Ogretmen, S. Galadari, B.-J. Kroesen, B. J. Pettus, and Y. A. Hannun FAS Activation Induces Dephosphorylation of SR Proteins. DEPENDENCE ON THE DE NOVO GENERATION OF CERAMIDE AND ACTIVATION OF PROTEIN PHOSPHATASE 1 J. Biol. Chem., November 21, 2001; 276(48): 44848 - 44855. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
